Treatment strategies in patients with major depression not responding to first-line sertraline treatment: A randomised study of extended duration of treatment, dose increase or mianserin augmentation

Psychopharmacology

Volumn 161, Issue 2, 2002, Pages 143-151

  Licht, Rasmus W ^a   Qvitzau, Susanne ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b PFIZER INC   (United States)

Author keywords

Depressive disorder; Drug combination; Drug therapy; Mianserin; Placebo; Randomised controlled trial; Sertraline

Indexed keywords

MIANSERIN; PLACEBO; SERTRALINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DETERIORATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MELANCHOLIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CONFIDENCE INTERVALS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIANSERIN; MIDDLE AGED; SERTRALINE; STATISTICS, NONPARAMETRIC;

EID: 0036250744     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-0999-0     Document Type: Article

References (27)

1. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression
2. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability
3. Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies
4. Does increasing dose improve efficacy in patients with poor antidepressant response: A review
5. Augmentation strategies for inadequate antidepressant response: A review of placebo-controlled studies
6. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression
7. Classification of side effects in psychopharmacology
8. Depressive illness
9. Effect of dose escalation after low-dose fluoxetine therapy
10. Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo
11. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone
12. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: A survey of current "next-step" practices
13. Fluoxetine
14. Combined treatment with imipramine and mianserin. A controlled pilot study
15. Epidemiology of depression: Prevalence, risk factors and treatment situation
16. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance
17. Mianserin added to tricyclic antidepressants in depressed patients not responding to a tricyclic antidepressant alone. A randomized, placebo-controlled, double-blind study
18. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: A survey of clinicians
19. Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: Studies with citalopram
20. Sertraline 50 mg daily: The optimal dose in the treatment of depression
21. The antidepressant effect of sertraline is not enhanced by dose titration: Results from an outpatient clinical trial
22. Why settle for silver, when you can go for gold? Response vs. recovery as the goal of antidepressant therapy